Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 3/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.55 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.54 |
| ▸ | CDC25A | P30304 | 2/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | POLA1 | P09884 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22894396 | 0.89 | VDR (0.74) | VDRUSP2ST6GAL1ABCC4 | |
| SCHEMBL22894394 | 0.89 | VDR (0.74) | VDRUSP2ST6GAL1ABCC4 | |
| SCHEMBL22894443 | 0.89 | VDR (0.74) | VDRUSP2ST6GAL1ABCC4 | |
| SCHEMBL22894586 | 0.89 | VDR (0.67) | VDRUSP2ST6GAL1ABCC4 | |
| SCHEMBL22894582 | 0.85 | VDR (0.67) | VDRUSP2ST6GAL1ABCC4 | |
| SCHEMBL23801842 | 0.80 | CDC25A (0.65) | VDRUSP2ST6GAL1CDC25APOLA1 | |
| SCHEMBL23801841 | 0.80 | CDC25A (0.65) | VDRUSP2ST6GAL1CDC25APOLA1 | |
| SCHEMBL23817171 | 0.80 | CDC25A (0.65) | VDRUSP2ST6GAL1CDC25APOLA1 | |
| SCHEMBL25433320 | 0.80 | CDC25A (0.65) | VDRUSP2ST6GAL1CDC25APOLA1 | |
| SCHEMBL23801844 | 0.80 | CDC25A (0.65) | VDRUSP2ST6GAL1CDC25APOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009569-A1 | SYNTHETIC RECEPTORS FOR IONOPHORIC COMPOUNDS | UNIVERSITEIT GENT (BE) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009569-A1 | SYNTHETIC RECEPTORS FOR IONOPHORIC COMPOUNDS | TACR1, VIPR1, QRFPR | VDR 312/4885USP2 4594/4885GRIN1 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.